Coast IRB closes doors after GAO sting

By Nick Taylor

- Last updated on GMT

Related tags: Institutional review board, Government accountability office

Coast IRB has decided to close after a probe by US Government Accountability Office (GAO) and subsequent FDA warning letter resulted in the loss of “several key customers”.

The institutional review board (IRB) was the focus of a GAO investigation that claimed the system is “vulnerable to unethical manipulation​”, which resulted in the company suspending some of its operations.

Coast had intended to initiate “immediate and sweeping reforms​” in an attempt to overhaul its operations but has now informed the US Food and Drug Administration (FDA), its clients and staff that it is to close “in the near future​”.

The IRB is currently arranging the transfer of its ongoing trials to other organisations and has reassured its clients that they will incur “no hassle or additional cost​”. This will entail the transfer of around 300 active trials to other accredited IRBs.

To smooth the transition staff associated with these trials may continue to support the studies after the transfer is complete. Coast has said other employees will be assisted with retraining and outplacement.

How Coast collapsed

Coast went from being a growing organisation with revenues of $9.3m (€7.1m) to shutting its doors in under a month, with the GAO probe and FDA warning letter scaring off existing and potential clients. 

The decision to approve a fictitious protocol for research in humans, which included false claims that the device was FDA-approved, led to calls for IRB reform and a warning letter for Coast.

Although the IRB initially hoped it could adapt and survive it appears the swift actions of some key clients have forced it to close, highlighting the pressure a scandal can put on a company.

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us

Products

View more

Webinars